Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does Incyte Corporation (INCY) Represent a Good Addition to Your Portfolio?

Page 1 of 2

The market has been volatile due to elections and the potential of another Federal Reserve rate increase. Small cap stocks have been on a tear, as the Russell 2000 ETF (IWM) has outperformed the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of June. SEC filings and hedge fund investor letters indicate that the smart money seems to be getting back in stocks, and the funds’ movements is one of the reasons why small-cap stocks are red hot. In this article, we analyze what the smart money thinks of Incyte Corporation (NASDAQ:INCY) and find out how it is affected by hedge funds’ moves.

There were 45 funds in our database that held shares of Incyte Corporation at the end of September. The company has experienced an increase in hedge fund interest, as there had been 32 funds with INCY positions at the end of the previous quarter. At the end of this article we will also compare INCY to other stocks including Rockwell Automation (NYSE:ROK), Essex Property Trust Inc (NYSE:ESS), and Ameriprise Financial, Inc. (NYSE:AMP) to get a better sense of its popularity.

Follow Incyte Corp (NASDAQ:INCY)
Trade (NASDAQ:INCY) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,

wavebreakmedia/Shutterstock.com

Now, let’s analyze the fresh action surrounding Incyte Corporation (NASDAQ:INCY).

Hedge fund activity in Incyte Corporation (NASDAQ:INCY)

At the end of the third quarter, a total of 45 funds tracked by Insider Monkey were bullish on Incyte Corporation, which represents an increase of 41% from the second quarter of 2016. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were increasing their holdings meaningfully (or already accumulated large positions).

HedgeFundSentimentChart

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Julian Baker and Felix Baker’s Baker Bros. Advisors has the number one position in Incyte Corporation (NASDAQ:INCY), worth close to $2.2157 billion, comprising 20.1% of its total 13F portfolio. Sitting at the No. 2 spot is OrbiMed Advisors, led by Samuel Isaly, holding a $174.5 million position; the fund has 2% of its 13F portfolio invested in the stock. Remaining professional money managers that hold long positions include David Goel and Paul Ferri’s Matrix Capital Management, Paul Marshall and Ian Wace’s Marshall Wace LLP, and Dmitry Balyasny’s Balyasny Asset Management.

Page 1 of 2
Loading Comments...